ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0356

Patient Satisfaction and Experience After a Switch to a Citrate-free High-concentration Adalimumab Biosimilar. Results from a Prospective Multicentric Real-world Study

Hubert Marotte1, Laure Gossec2, Vered ABITBOL3, Eric SENBEL4, Guillaume BONNAUD5, Xavier ROBLIN6, Yoram BOUHNIK7, Stéphane NANCEY8, Nicolas MATHIEU9, jérôme FILIPPI10, Lucine VUITTON11, Stéphane NAHON12, Azeddine Dellal12, Alice DENIS13, Caroline HABAUZIT13, Salim BENKHALIFA13 and Guillaume BOUGUEN14, 1Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, 2Sorbonne Université, Paris, France, 3Cochin University Hospital, Paris, France, 4Medical practice, Marseille, Marseille, France, 5Ambroise Paré Clinic, Toulouse, France, 6Saint-Etienne University Hospital, Saint-Etienne, France, 7Institut des MICI, Paris IBD Center, Neuilly-Sur-Seine, France, 8Hospices Civils de Lyon, Lyon, France, 9Clinic of Cèdres, Echirolles, France, 10Saint-Jean Clinic, Cagnes sur Mer, France, 11Besançon university hospital, Besançon, France, 12Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France, 13Celltrion Healthcare France, Issy Les Moulineaux, France, 14Rennes University Hospital, Rennes, France

Meeting: ACR Convergence 2024

Keywords: Anti-TNF Drugs, pain, Patient reported outcomes, rheumatoid arthritis, Spondyloarthropathies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Patient Outcomes, Preferences, & Attitudes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Biosimilars (BioS) are cost-effective alternatives to reference products for patients with chronic inflammatory rheumatic diseases (CIRD) and inflammatory bowel diseases (IBD), but treatment adherence and maintenance after such a transition is linked to patient overall experience that could be impacted by patient or treatment characteristics. This study aimed to explore patient experience and satisfaction after the transition to a high-concentration citrate-free adalimumab biosimilar, CT-P17.

Methods: YU-MATTER (NCT05427942), a prospective observational French study included patients with chronic inflammatory rheumatic disease (CIR) or inflammatory bowel disease already treated with adalimumab (ADA), either the RP (HC: 100mg/mL) or a BioS with low concentration (LC: 50 mg/mL). Patients were switched to CT-P17 and followed-up for 3 months (M). Patient characteristics were collected at M0, as well as their treatment experience at M0, M1, M2, and M3 via 5 self-reported questionnaires developed in collaboration with patient associations to explore satisfaction regarding the injection (Likert 7), discomfort (pain [Numeric Rating Scale, NRS 0-10], redness [Likert 4], itching [NRS 0-10], and haematoma [Likert 3]). Satisfaction and overall injection tolerance (pain and itching scores < 4 + no redness + no haematoma) were assessed between M0 (just before switch) and M3 (3 months after the switch). The Last Observation Carried Forward (LOCF) method was used to replace missing data at M3. Factors associated with satisfaction improvement between M0 and M3 (increase of at least two points on the Likert 7) were searched in patients evaluable at both time-points using multivariable logistic regression models.

Results: 232 patients were included (CIRD: 28.0% in whom 17 rheumatoid arthritis, 35 ankylosing spondylitis, 7 non-radiographic axial spondyloarthritis and 6 psoriatic arthritis; IBD: 72.0%, in whom 136 Crohn’s disease) by 11 rheumatologists and 17 gastroenterologists. In the global population, patient age was 44±15 years, 50.4% were men, and median disease duration was 9 years (IQR: 5-16). 119 (51.2%) patients were switched from an ADA-BioS (45 with citrate, 19.4%) and 113 (48.7%) from RP-ADA. At M3, patient satisfaction did not decrease after switching. More patients reported an increased satisfaction after switching from ADA-BioS (22.7% versus 8.0%, p=0.002) or ADA with citrate (28.9% versus 12.3% p=0.008) (Figure1). Independent prognostic factors of an increased satisfaction were a previous ADA-BioS (OR=2.88; 95%CI [1.17-7.08]; p=0.021), and pain at the injection site under the previous ADA (OR=1.26 [1.08-1.47], p=0.004). Patients significantly reported less pain, redness, itching, and hematoma at M3 (p< 0.001).

Conclusion: This real-world prospective study showed that the global experience of patients after the switch to CT-P17, a high concentration and citrate-free biosimilar of the reference adalimumab, was positive with no decrease in satisfaction with treatment, and a significant improvement in overall injection tolerance.

Supporting image 1


Disclosures: H. Marotte: AbbVie/Abbott, 4, 5, 6, Biogen, 5, 6, Bristol-Myers Squibb(BMS), 5, 6, Celltrion Healthcare, 5, 6, Eli Lilly, 5, 6, Fresenius Kabi, 5, 6, Galapagos, 5, 6, Janssen, 5, 6, Merck/MSD, 5, 6, Nordic Pharma, 5, 6, Novartis, 5, 6, Pfizer, 5, 6, Roche, 5, 6, Sanofi, 5, 6; L. Gossec: AbbVie, 2, 5, Amgen, 2, Biogen, 5, Bristol-Myers Squibb (BMS), 2, Celltrion, 2, Eli Lilly, 2, 5, Galapagos, 2, Janssen, 2, MSD, 2, Novartis, 2, 5, Pfizer, 2, Sandoz, 2, UCB, 2, 5; V. ABITBOL: AbbVie/Abbott, 5, 6, Amgen, 5, 6, Celltrion Healthcare, 5, 6, Eli Lilly, 5, 6, Ferring, 5, 6, Fresenius Kabi, 5, 6, Galapagos, 5, 6, Janssen, 5, 6, Nordic Pharma, 5, 6, Pfizer, 5, 6, Sandoz, 5, 6, Takeda, 5, 6, Tillotts, 5, 6, Viatris, 5, 6; E. SENBEL: AbbVie/Abbott, 5, 6, Celltrion Healthcare, 5, 6, Eli Lilly, 5, 6, Fresenius Kabi, 5, 6, IQVIA, 5, 6, Nordic Pharma, 5, 6, Sandoz, 5, 6, UCB, 5, 6; G. BONNAUD: AbbVie/Abbott, 5, 6, Alfasigma, 5, 6, Bouchara Recordati, 5, 6, Celltrion Healthcare, 5, 6, Ferring, 5, 6, Galapagos, 5, 6, Gilead, 5, 6, Janssen, 5, 6, Medtronic, 5, 6, Merck/MSD, 5, 6, Norgine, 5, 6, Pfizer, 5, 6, Roche, 5, 6, Sandoz, 5, 6, Takeda, 5, 6, Tillotts, 5, 6, Viatris, 5, 6; X. ROBLIN: AbbVie/Abbott, 5, 6, Amgen, 5, 6, Celltrion Healthcare, 5, 6, Eli Lilly, 5, 6, Ferring, 5, 6, Janssen, 5, 6, Pfizer, 5, 6, Takeda, 5, 6, Theradiag, 5, 6; Y. BOUHNIK: AbbVie/Abbott, 5, 6, Alimentiv, 5, 6, Amgen, 5, 6, Biogaran, 5, 6, Biogen, 5, 6, Boehringer-Ingelheim, 5, 6, Celltrion Healthcare, 5, 6, Eli Lilly, 5, 5, 6, 6, Ferring, 5, 6, Fresenius Kabi, 5, 6, Galapagos, 5, 6, Gilead, 5, 6, Hospira, 5, 5, 6, 6, iterative Health, 5, 6, Janssen, 5, 6, Mayoli Spindler, 5, 6, Merck/MSD, 5, 6, Norgine, 5, 6, Pfizer, 5, 6, Roche, 5, 6, Sandoz, 5, 6, Sanofi, 5, 6, Shire, 5, 6, Takeda, 5, 6, Tillotts, 5, 6, UCB, 5, 6, Viatris, 5, 6; S. NANCEY: AbbVie/Abbott, 5, 6, Amgen, 5, 6, Biogen, 5, 6, Celltrion Healthcare, 5, 6, Eli Lilly, 5, 6, Fresenius Kabi, 5, 6, Galapagos, 5, 6, Janssen, 5, 6, Pfizer, 5, 6, Sandoz, 5, 6, Takeda, 5, 6; N. MATHIEU: Celltrion Healthcare, 5, 6; j. FILIPPI: AbbVie/Abbott, 5, 6, Amgen, 5, 6, Biogen, 5, 6, Celltrion Healthcare, 5, 6, Ferring, 5, 6, HAC Pharma, 5, 6, Janssen, 5, 6, Merck/MSD, 5, 6, Pfizer, 5, 6, Sandoz, 5, 6, Takeda, 5, 6; L. VUITTON: AbbVie/Abbott, 5, 6, Amgen, 5, 6, Celltrion Healthcare, 5, 6, Eli Lilly, 5, 6, Ferring, 5, 6, Galapagos, 5, 6, Janssen, 5, 6, Merck/MSD, 5, 6, Pfizer, 5, 6, Takeda, 5, 6, Viatris, 5, 6; S. NAHON: AbbVie/Abbott, 5, 6, Amgen, 5, 6, Biogen, 5, 6, Celltrion Healthcare, 5, 6, Ferring, 5, 6, Galapagos, 5, 6, Janssen, 5, 6, Merck/MSD, 5, 6, Takeda, 5, 6, Tillotts, 5, 6; A. Dellal: AbbVie/Abbott, 5, 6, Celltrion Healthcare, 5, 6, Fresenius Kabi, 5, 6; A. DENIS: Celltrion Healthcare, 3; C. HABAUZIT: Celltrion Healthcare, 3; S. BENKHALIFA: Celltrion Healthcare, 3; G. BOUGUEN: AbbVie/Abbott, 5, 6, Amgen, 5, 6, Biogen, 5, 6, Celltrion Healthcare, 5, 6, Eli Lilly, 5, 6, Fresenius Kabi, 5, 6, Galapagos, 5, 6, Gilead, 5, 6, Janssen, 5, 6, Pfizer, 5, 6, Sandoz, 5, 6, Takeda, 5, 6.

To cite this abstract in AMA style:

Marotte H, Gossec L, ABITBOL V, SENBEL E, BONNAUD G, ROBLIN X, BOUHNIK Y, NANCEY S, MATHIEU N, FILIPPI j, VUITTON L, NAHON S, Dellal A, DENIS A, HABAUZIT C, BENKHALIFA S, BOUGUEN G. Patient Satisfaction and Experience After a Switch to a Citrate-free High-concentration Adalimumab Biosimilar. Results from a Prospective Multicentric Real-world Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/patient-satisfaction-and-experience-after-a-switch-to-a-citrate-free-high-concentration-adalimumab-biosimilar-results-from-a-prospective-multicentric-real-world-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-satisfaction-and-experience-after-a-switch-to-a-citrate-free-high-concentration-adalimumab-biosimilar-results-from-a-prospective-multicentric-real-world-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology